A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders

Pharmacological Research, Год журнала: 2025, Номер 213, С. 107657 - 107657

Опубликована: Фев. 19, 2025

Research carried out during the last 30 years since first identification of CB2r in 1993 has changed landscape this receptor's role and therapeutic utility. Initially, studies focused on elucidating at periphery it was characterized spleen lymphocytes. Later, found brain not only under pathological conditions but also basal conditions. It is now known that receptor expressed different regions cell types, including neurons microglia. Experimental have provided robust evidence involved modulation immune system, neuroinflammation, oxidative stress neuroprotection. Besides, mediated response to stress, anxiety, depression. Also, plays a relevant modulating reinforcing properties drugs abuse, alcohol, nicotine cocaine. In review, we summarize cumulative knowledge regarding immunomodulatory, anti-inflammatory, antioxidant, neuroprotective against development neurodegenerative diseases. Indeed, cover anxiolytic antidepressant potential CB2r, which raises interest psychiatric diseases associated with anxiety Finally, discuss involvement regulation drug addiction. A better understanding essential for pharmacological neurodegenerative, psychiatric, addictive disorders.

Язык: Английский

---

Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges

Stresses, Год журнала: 2025, Номер 5(1), С. 7 - 7

Опубликована: Янв. 15, 2025

Chronic pain represents a complex and debilitating condition that affects millions of people worldwide, significantly compromising their quality life. The conventional approach to treating this type often relies on the use opioid analgesics anti-inflammatory drugs. While these agents are effective in short term, they present several limitations, including risk dependence, severe side effects, and, some cases, ineffectiveness reducing pain. In context, medical cannabis has emerged as promising therapeutic alternative, given its potential ability relieve effectively with favorable safety profile. This work aims provide comprehensive up-to-date review existing literature effects treatment chronic Cannabis sativa contains pharmacologically active compounds, most prominent which delta-9-tetrahydrocannabinol (∆9-THC) cannabidiol (CBD), interact body’s endocannabinoid system, thereby modulating response. Clinical evidence shown cannabinoids can reduce intensity pain, particularly cases neuropathy, multiple sclerosis, arthritis, other painful conditions unresponsive treatments. However, full integration into clinical practice faces significant obstacles, need for standardized dosing, long-term data, regulatory frameworks. These issues, alongside concerns over adverse drug interactions, must be addressed unlock cannabinoids, patients, who endure both physical suffering added burden stress.

Язык: Английский

---

Síndrome de hiperémesis cannabinoide: una revisión

Revista de Gastroenterología de México, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

---

Cannabinoid hyperemesis syndrome-an emerging gastrointestinal disorder and clinical challenge

Disease-a-Month, Год журнала: 2024, Номер unknown, С. 101832 - 101832

Опубликована: Дек. 1, 2024

Язык: Английский

---

Nausea and vomiting – General considerations

Disease-a-Month, Год журнала: 2024, Номер unknown, С. 101831 - 101831

Опубликована: Дек. 1, 2024

Язык: Английский

---

Gastrointestinal disorders – Clinical challenges for the primary care clinician

Disease-a-Month, Год журнала: 2024, Номер unknown, С. 101828 - 101828

Опубликована: Дек. 1, 2024

Язык: Английский

---

The Role of Cannabinoids and the Endocannabinoid System in the Treatment and Regulation of Nausea and Vomiting

Current topics in behavioral neurosciences, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Язык: Английский

---